Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma

Part of paid clinical trials in Bethesda, Maryland.

Sponsor
National Cancer Institute (NCI)
Study ID
NCT00058279
Phase
PHASE1/PHASE2
Status
Completed

Conditions

  • Intraocular Melanoma
  • Melanoma (Skin)

Eligibility Criteria

Sex
ALL
Age
16 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • aldesleukin — BIOLOGICAL
  • ipilimumab — BIOLOGICAL

Study Details

RATIONALE: Biological therapies, such as MDX-010, work in different ways to stimulate the immune system and stop tumor cells from growing. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Combining monoclonal antibody therapy with interleukin-2 may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combining monoclonal antibody therapy with interleukin-2 in treating patients who have metastatic melanoma.

Key Dates

Start date
Feb 28, 2003
Status verified
Aug 2006
Completion
Aug 31, 2006

Study Design

Primary purpose
TREATMENT

Locations (1)

FacilityCityStateZIPSite coordinators
Warren Grant Magnuson Clinical Center - NCI Clinical Studies SupportBethesdaMaryland20892-1182-

Find similar trials in Bethesda, MD

By research site
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support· Bethesda, MD

Related Studies